Fund II Team
Senior Managing Partner
Dr. Paul Castella has experience in the evaluation, financing, licensing, formation and operation of biotechnology and medical technology companies. Paul specializes in financing and licensing strategies for technology start-ups, and in 2009, Paul cofounded (with Alan Dean) Targeted Technology Fund I, LP. Previously, Paul co-founded and served as the President and CFO of CardioSpectra, which was formed in late 2005 and acquired by Volcano Corporation (NASDAQ: VOLC) in December 2007 for $63M in upfront payments and milestones.
Other companies Paul has co-founded, managed and financed include Xenotope Diagnostics (novel rapid STD test), ViroXis Corporation (anti-viral botanical drug), BiO2 Medical (Angel™ Catheter for the prevention of pulmonary embolism), and Santalis Pharmaceuticals (botanical drug development). Paul is a board member for Xenotope Diagnostics, BioDtech, BiO2 Medical, ViroXis Corporation, Santalis Pharmaceuticals, StemBioSys and Soluble Therapeutics, and an advisory board member of the Chromosome 18 Registry, the Center for Technology Entrepreneurship and Innovation at UTSA (CITE), and the University of Texas San Antonio School of Business.
Paul received his PhD in Cell Biology and Genetics from Cornell University Medical College in Manhattan, where he was the first-ever recipient of the Weill Graduate School Award of Excellence. He received his MBA from the University of Texas at San Antonio. Paul holds numerous issued and pending patents, and in 2008 was inducted into San Antonio’s “SATAI Technology Hall of Fame.”